Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol MRI for response assessment to Keytruda in glioblastoma
NCT03347617Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Dec 2017
- Primary completion
- Dec 2023
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ferumoxytol in glioblastoma (GBM), sponsored by OHSU Knight Cancer Institute. Started Dec 2017; status: terminated.
02
Drugs
ferumoxytol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03347617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347617.